Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis
Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis
复制标题
DOI：
10.1016/s0022-5347(01)68155-2
复制
发表时间：
1997-12-01
影响因子：
6.6
通讯作者：
Vangessel, A
中科院分区：
文献类型：
--
作者：
Ettinger, B;Pak, CYC;Vangessel, A
目的：我们研究了柠檬酸钾镁在预防草酸钙肾结石复发中的疗效。材料和方法：我们进行了一项前瞻性双盲研究，64例患者被随机分配接受安慰剂或柠檬酸钾镁（42 mEq.钾，21毫当量。镁和63 mEq。柠檬酸盐），持续3年。63.6%接受安慰剂的受试者和12.9%接受柠檬酸钾镁的受试者形成新结石。与安慰剂相比，枸橼酸钾镁治疗失败的相对风险为0.16（95%置信区间为0.05 - 0.46）。柠檬酸钾镁对（相对危险度0.10，95%可信区间0.03 ~ 0.36），即使调整了可能的混杂因素，包括年龄、治疗前结石事件率和尿生化异常。柠檬酸钾镁有效预防草酸钙结石复发，这种治疗长达3年，可将复发风险降低85%。
Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi.Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years.Results. New calculi formed in 63.6% of subjects receiving placebo and in 12.9% of subjects receiving potassium-magnesium citrate. When compared with placebo, the relative risk of treatment failure for potassium-magnesium citrate was 0.16 (95% confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10, 95% confidence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.Conclusions: Potassium-magnesium citrate effectively prevents recurrent calcium oxalate stones, and this treatment given for up to 3 years reduces risk of recurrence by 85%.